Tharimmune Corp (THAR): חובות להיוון בספרים

Tharimmune, Inc. relies on external contractors for drug development, while management focuses on cost optimization and prioritizing research. The historical ratio of financial debt to book capitalization confirms the current financial burden, where 0.03 determines the current value of the metric. The current lack of revenue is offset by the potential high value of future innovative cancer therapies.

This indicator determines the financial stability of assets through the ratio of total liabilities to net book capital. The metric reveals hidden imbalances where excessive leverage is masked by trading optimism. By analyzing the debt-to-equity ratio on the balance sheet, an investor assesses the risk of default or the potential for credit expansion. For Tharimmune, Inc. (THAR), a low debt level is critical, ensuring survival during the period of costly immunotherapy development. This guarantees stable funding for antibody research without dependence on borrowed capital.